TVTX Travere Therapeutics Inc.
Health Care, filed as TRAVERE THERAPEUTICS INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
Bought by 1 manager in 2026 Q3, sold by 1
In 2026 Q3 Polen Capital Management added to Travere Therapeutics, while Palo Alto Investors trimmed.
Who owns this now
Largest portfolio weights among holders, up to 1.4% (Palo Alto Investors). Not free-float ownership.
Who owns TVTX
Sorted by value, long equity only, as of 2026 Q3.
| History | |||||
|---|---|---|---|---|---|
| Palo Alto Investors | Reduce −5.1% | 158,946 | $9.4M | History | |
| Polen Capital Management | Add +54.4% | 52,988 | $3.1M | History |
Insider trades
Open-market buys and sales by TVTX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $99.1M sold by 11 insiders under 10b5-1 plans
-
Eric M. Dube CEOPlanned sale$13.1M 243,735 shares at $53.82 36% of stakeTraded Oct 15 Filed Oct 19
-
Christopher R. Cline CFOPlanned sale$3.1M 50,508 shares at $62.34 37% of stakeTraded Sep 15 Filed Sep 17
-
Jula Inrig EVP, Head of R&D & CMOPlanned sale$2.8M 44,674 shares at $62.34 31% of stakeTraded Sep 15 Filed Sep 17
-
Sandra Calvin SVP, Chief Accounting OfficerPlanned sale$335K 5,375 shares at $62.33 11% of stakeTraded Sep 15 Filed Sep 17
-
Peter Heerma EVP, Chief Commercial OfficerPlanned sale$17.9M 283,189 shares at $63.06 71% of stakeTraded Sep 15–17 Filed Sep 17
-
Eric M. Dube CEOPlanned sale$25.4M 400,000 shares at $63.48 48% of stakeTraded Sep 15–17 Filed Sep 17
-
William E. Rote Chief Research OfficerPlanned sale$13.1M 209,048 shares at $62.83 68% of stakeTraded Sep 15–16 Filed Sep 17
-
Elizabeth E. Reed Chief Legal Officer and GCPlanned sale$2.3M 37,500 shares at $62.34 26% of stakeTraded Sep 15 Filed Sep 17
-
Jeffrey A. Meckler DirectorPlanned sale$1.3M 20,000 shares at $67.31 18% of stakeTraded Sep 10 Filed Sep 11
-
Gary A. Lyons DirectorPlanned sale$633K 10,000 shares at $63.28 14% of stakeTraded Aug 17–18 Filed Aug 19
-
Roy D. Baynes DirectorPlanned sale$225K 4,500 shares at $50.00 9.8% of stakeTraded Jun 12 Filed Jun 16
-
Timothy Coughlin DirectorPlanned sale$501K 10,000 shares at $50.07 15% of stakeTraded Jun 12 Filed Jun 16
-
Timothy Coughlin DirectorPlanned sale$141K 3,250 shares at $43.49 5.9% of stakeTraded May 15 Filed May 19
-
Jula Inrig Chief Medical OfficerPlanned sale$900K 20,000 shares at $45.00 15% of stakeTraded May 4 Filed May 6
-
Roy D. Baynes DirectorPlanned sale$210K 4,500 shares at $46.65 11% of stakeTraded May 5 Filed May 6
Also filed in the last 12 months, not counted as buying or selling: 64 option exercises, 40 sales to cover taxes, 22 stock grants, and 1 gift.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 5.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.02 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total current assets | $616.78M | $416.7M | $437.56M |
| Total non-current assets * | $172.14M | $177.42M | $167.63M |
| Total assets | $788.91M | $594.12M | $605.19M |
| Total current liabilities | $177.91M | $200.75M | $159.9M |
| Total non-current liabilities * | $410.2M | $334.3M | $330.46M |
| Total equity | $200.81M | $59.08M | $114.83M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon